EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes

Tatiana A. Bykova, A. A. Osipova, O. A. Slesarchuk, E. E. Zakharov, L. S. Zubarovskaya, A. D. Kulagin

Pediatric Hematology/Oncology and Immunopathology · 30.06.2026 · 25 (2) · 25-36

DOI: 10.24287/j.1136 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Hematology/Oncology and Immunopathology, online erschienen am 30.06.2026. Verfasst von Tatiana A. Bykova und 5 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Inherited bone marrow failure syndromes (IBMFS) constitute a heterogeneous group of rare genetic disorders associated with impaired hematopoiesis, congenital anomalies, and a high risk of transformation to myelodysplastic syndrome and acute myeloid leukemia. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for IBMFS. Aim: to identify factors determining the efficacy of allo-HSCT in pediatric patients with IBMFS. Materials and methods. This study analyzed data from 61 patients with IBMFS who had undergone allo-HSCT between 2005 and 2025 at the R.M. Gorbacheva Research Institute of Pediatric Oncology, Hematology and Transplantation.

Results

The median follow-up was 24 months. The overall survival (OS) at 1, 3, and 5 years post-transplantation was 88%, 85%, and 81%, respectively. The lowest 5-year OS was observed in the Fanconi anemia (47%) and Diamond–Blackfan anemia (86%) groups, whereas in the patients with other IBMFS the 5-year OS reached 100% (p = 0.003). Factors associated with improved survival included age younger than 5 years at transplantation (100% vs. 68%; p = 0.009), the use of myeloablative conditioning regimens (100% vs. 64.5%; p = 0.002), the use of post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis (100% vs. 67%; p = 0.02), and successful engraftment (88% vs. 33%; p = 0.002). GVHD prophylaxis regimens without calcineurin inhibitors were associated with a lower incidence of grade II–IV acute GVHD (11% vs. 44%; p = 0.03) and a reduced need for switching immunosuppression (5% vs. 35%; p = 0.02). Donor type and degree of HLA matching did not significantly affect survival.

Conclusion

Allo-HSCT is a highly effective treatment for children with IBMFS, providing a 5-year OS of 81%. The best outcomes are achieved with allo-HSCT performed at an early age (under 5 years), the use of myeloablative conditioning regimens (when not contraindicated), and with the addition of PTCy to GVHD prophylaxis. The lowest survival was observed in the patients with Fanconi anemia, highlighting the need for further refinement of treatment protocols for this patient group. PTCy-based GVHD prophylaxis regimens without calcineurin inhibitors reduce the incidence of acute GVHD and improve the tolerability of immunosuppression.

Zitieren

APA

Bykova, T. A., Osipova, A. A., Slesarchuk, O. A., Zakharov, E. E., Zubarovskaya, L. S., & Kulagin, A. D. (2026). Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes. Pediatric Hematology/Oncology and Immunopathology, 25(2), 25-36. https://doi.org/10.24287/j.1136

Vancouver

Bykova TA, Osipova AA, Slesarchuk OA, Zakharov EE, Zubarovskaya LS, Kulagin AD. Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes. Pediatric Hematology/Oncology and Immunopathology. 2026;25(2):25-36. doi:10.24287/j.1136

BibTeX
@article{Bykova2026,
  author = {Bykova, Tatiana A. and Osipova, A. A. and Slesarchuk, O. A. and Zakharov, E. E. and Zubarovskaya, L. S. and Kulagin, A. D.},
  title = {Factors determining successful allogeneic hematopoietic stem cell transplantation in children with inherited bone marrow failure syndromes},
  journal = {Pediatric Hematology/Oncology and Immunopathology},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {25--36},
  doi = {10.24287/j.1136}
}
Kostenlos starten →